Literature DB >> 16504641

Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: an intravascular ultrasound study.

Hideaki Kaneda1, Mitsuyasu Terashima, Takefumi Takahashi, Stein Iversen, Thomas Felderhoff, Eberhard Grube, Paul G Yock, Yasuhiro Honda, Peter J Fitzgerald.   

Abstract

BACKGROUND: Previous long-term (>1 year) studies have suggested that saphenous vein bypass grafts (SVGs) undergo vascular remodeling similar to native coronary arteries. However, early morphologic stages of SVG remodeling have not been characterized in vivo.
METHODS: Thirty SVGs were studied 12 months after implantation using an intravascular ultrasound automated pullback system. Intravascular ultrasound images were analyzed between 10 and 60 mm from the tip of the guide. Lumen area (LA), intima area (IA), and vessel area (VA, defined as the area within the outer border of a hypoechoic intimal layer) were computed at 3 cross sections: the minimum LA (MLA) site and the proximal and distal reference sites. Area changes (Delta) were calculated as the MLA site minus the average of the reference sites.
RESULTS: In this cohort, 70% of the MLA sites had a smaller VA than the average references. On average, MLA sites had significantly smaller VA (9.7 +/- 2.9 vs 10.7 +/- 3.2 mm2, P < .01) and larger IA (2.5 +/- 2.1 vs 1.2 +/- 1.3 mm2, P < .01) than at the reference sites. The relative contribution of DeltaVA (-1.0 +/- 1.4 mm2) and DeltaIA (1.3 +/- 1.3 mm2) to lumen compromise (-2.3 +/- 1.4 mm2) were 43% and 57%, respectively. On the other hand, simple linear regression analysis revealed a significant positive correlation between DeltaIA and DeltaVA (y = -1.7 + 0.52x, r = 0.50, P < .01).
CONCLUSIONS: Within the first year, the mechanism of lumen compromise in SVG is a combination of negative remodeling and intimal hyperplasia. Positive remodeling is seen in a minority of cases. However, the direction and extent of remodeling correlated with change in intimal thickness.

Entities:  

Mesh:

Year:  2006        PMID: 16504641     DOI: 10.1016/j.ahj.2005.05.011

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  Scavenger receptor class A member 5 (SCARA5) and suprabasin (SBSN) are hub genes of coexpression network modules associated with peripheral vein graft patency.

Authors:  Richard D Kenagy; Mete Civelek; Shinsuke Kikuchi; Lihua Chen; Anthony Grieff; Michael Sobel; Aldons J Lusis; Alexander W Clowes
Journal:  J Vasc Surg       Date:  2015-04-30       Impact factor: 4.268

2.  Reproducibility of optical coherence tomography in vein grafts used for coronary revascularization.

Authors:  Øystein Pettersen; Elżbieta Pociask; Krzysztof P Malinowski; Magdalena Slezak; Knut Hegbom; Rune Wiseth; Dag Ole Nordhaug
Journal:  Cardiol J       Date:  2018-11-16       Impact factor: 2.737

3.  A single nucleotide polymorphism of cyclin-dependent kinase inhibitor 1B (p27Kip1) associated with human vein graft failure affects growth of human venous adventitial cells but not smooth muscle cells.

Authors:  Richard D Kenagy; Shinsuke Kikuchi; Lihua Chen; Errol S Wijelath; Andrew B Stergachis; John Stamatoyannopoulos; Gale L Tang; Alexander W Clowes; Michael Sobel
Journal:  J Vasc Surg       Date:  2017-05-16       Impact factor: 4.268

4.  Saphenous vein graft near-infrared spectroscopy imaging insights from the lipid core plaque association with clinical events near-infrared spectroscopy (ORACLE-NIRS) registry.

Authors:  Barbara A Danek; Aris Karatasakis; Aya J Alame; Phuong-Khanh J Nguyen-Trong; Judit Karacsonyi; Bavana Rangan; Michele Roesle; Amy Atwell; Erica Resendes; Jose Roberto Martinez-Parachini; Rahel Iwnetu; Pratik Kalsaria; Furqan Siddiqui; James E Muller; Subhash Banerjee; Emmanouil Brilakis
Journal:  Catheter Cardiovasc Interv       Date:  2016-08-18       Impact factor: 2.692

5.  Immobilized contrast-enhanced MRI: Gadolinium-based long-term MR contrast enhancement of the vein graft vessel wall.

Authors:  Dimitris Mitsouras; Praveen Kumar Vemula; Peng Yu; Ming Tao; Binh T Nguyen; Christina M Campagna; Jeffrey M Karp; Robert V Mulkern; C Keith Ozaki; Frank J Rybicki
Journal:  Magn Reson Med       Date:  2011-01       Impact factor: 4.668

Review 6.  Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications.

Authors:  Christopher D Owens
Journal:  J Vasc Surg       Date:  2009-10-17       Impact factor: 4.268

7.  Early animal model evaluation of an implantable contrast agent to enhance magnetic resonance imaging of arterial bypass vein grafts.

Authors:  Dimitrios Mitsouras; Ming Tao; Margreet R de Vries; Kaspar Trocha; Oscar R Miranda; Praveen Kumar Vemula; Kui Ding; Amir Imanzadeh; Frederick J Schoen; Jeffrey M Karp; C Keith Ozaki; Frank J Rybicki
Journal:  Acta Radiol       Date:  2018-01-29       Impact factor: 1.990

8.  Diet-induced obesity drives negative mouse vein graft wall remodeling.

Authors:  Peng Yu; Binh T Nguyen; Ming Tao; Tianyu Jiang; C Keith Ozaki
Journal:  J Vasc Surg       Date:  2013-07-19       Impact factor: 4.268

9.  Early remodeling of lower extremity vein grafts: inflammation influences biomechanical adaptation.

Authors:  Christopher D Owens; Frank J Rybicki; Nicole Wake; Andres Schanzer; Dimitrios Mitsouras; Marie D Gerhard-Herman; Michael S Conte
Journal:  J Vasc Surg       Date:  2008-04-28       Impact factor: 4.268

10.  A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

Authors:  Olivier F Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence Title; Vladimir Dzavik; Madhu Natarajan; Juan Angel; Nuria Batalla; Natalie Alméras; Olivier Costerousse; Robert De Larochellière; Louis Roy; Jean-Pierre Després
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.